About Blood Cancer Discovery
Blood Cancer Discovery will provide a critical outlet for high-impact basic, translational, and clinical research on all disease subtypes of leukemia, lymphoma, myeloma, and associated diseases. Studies published in Blood Cancer Discovery will describe mechanisms underlying disease biology; diagnostic and therapeutic development; and translation of these data into clinical trials.
Blood Cancer Discovery welcomes submissions of primary research, review and commentary article types as well as letters to the editor. For descriptions and length requirements of the article types available to submitting authors, see the journal’s Categories of Articles.
The AACR Journals all use a similar Editorial Process and adhere to the same overarching Editorial Policies, both of which are detailed in the Information for Authors. These instructions contain important guidelines on authorship, publishing ethics, availability of materials and data, and data analysis and reporting. Authors should be familiar with these instructions prior to submitting their work to the journal. Manuscripts are stringently reviewed for high standards of scientific merit, and only those that report results of novel, timely, and broadly-significant research are accepted for publication.
Submit your article to Blood Cancer Discovery
Blood Cancer Discovery metrics are not yet available.
Editorial oversight of Blood Cancer Discovery and decisions on manuscripts submitted to the journal are the responsibility of the Editorial Board with support from journal staff. See Editorial Board for more information.
Copyright, Permissions and Access
Material published in Blood Cancer Discovery is covered and protected by copyright. Authors who wish to publish in the journal must formally transfer copyright to the AACR but are granted considerable reuse rights. The final typeset version of every published article is rendered freely accessible 12 months after publication. Authors who prefer for their article to be immediately freely accessible online may make this selection by paying an additional fee through the AACR AuthorChoice option. In addition, the AACR assists authors in satisfying major funder Open Access archiving mandates by depositing the accepted author version of their article in a designated public repository. For additional details about all these topics, see Copyright, Permissions and Access.
Publication and color fees for Blood Cancer Discovery will be waived through December 31, 2020.
Blood Cancer Discovery (BCD) (Print ISSN: 2643-3230; Online ISSN: 2643-3249) is published once a month, one volume/year, by the American Association for Cancer Research, Inc. (AACR).
Blood Cancer Discovery is abstracted and/or indexed in BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.
The journal is printed on paper that meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
Back Issues and Single Issue Sales
Subject to availability, single or back issues of Blood Cancer Discovery may be purchased for $60 per copy in the U.S. or $65 per copy outside the U.S. For more information, contact:
AACR Publications Sales & Marketing Department
American Association for Cancer Research
615 Chestnut Street, 17th Floor
Philadelphia, PA 19106-4404
Phone: (215) 440-9300; or Toll Free: (855) 744-4667
Blood Cancer Discovery Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 440-9354 | E-mail: email@example.com